MOCA is a leading player in the Australian cannabis market, with a unique business model that focuses on a staged approach to executing its business plan. Currently, MOCA is a fully licensed importer and exporter of all cannabis-based medications into and out of Australia. This licensing enables MOCA to bring a variety of medical cannabis products into its secure medical facility in New South Wales, including flowers, CBD and THC capsules, CBD oils and tinctures, sub-lingual and concentrates.

MOCA is working with national and international cultivators of low THC, high-level CBD cannabis of very good quality. The changing landscape in the legal Italian cannabis industry is providing an excellent opportunity. MOCA has made contacts with various associations around the Italian regions and is working to create a consortium of growers supported by the European Union. MOCA is leveraging its licenses to bring high-quality, low-cost medical cannabis products to Australia, which is expected to create a strong strategic advantage over competitors.

In addition to its import and export capabilities, MOCA also owns and operates MOCA Health, a leading online telehealth clinic founded in 2022. The clinic provides medical cannabis consultations to patients, enabling MOCA to onboard patients directly through its online platform developed in conjunction with licensed medical cannabis doctors. MOCA is developing educational materials specifically for medical professionals to assist in prescribing MOCA's cannabis products. This strategy is expected to increase the company's patient base and revenue streams, while also building trust and credibility in the medical community.

MOCA has supply agreements with licensed cannabis cultivators in the United States and in Canada that enables it to import products into Australia immediately. 

The main source of revenue for MOCA is wholesale of cannabis biomass and finished medications to the healthcare industry internationally and in Australia. The company specifically targets medical cannabis clinics and licensed doctors. In Australia, MOCA has agreements in place with licensed doctors and medical licensed clinics. MOCA's business model is designed to be scalable, with the ability to expand into new markets as regulations change.

For sophisticated investors interested in investing in MOCA, the company's unique business model and strategic partnerships position it for strong growth potential in the Australian and international cannabis markets. MOCA's focus on organic cannabis, sustainable farming practices, and high-quality medical cannabis products, combined with its telehealth clinic, provides a competitive advantage over other cannabis companies in the market. The company's staged approach to executing its business plan, along with its import and export licenses, is expected to create significant revenue streams and increase shareholder value in the long run.

However, investors should carefully consider the risks and potential rewards before making any investment decisions in the cannabis industry. The cannabis industry is still relatively new and faces regulatory and legal challenges in many markets. In Australia, the regulatory framework for medicinal cannabis is still evolving, and there is uncertainty about how the market will develop in the coming years. MOCA's success is closely tied to the regulatory environment, and any changes could have a significant impact on the company's operations and financial performance. As with all investments, it is important to conduct thorough due diligence before making any investment decisions in the cannabis industry.